What Is the Correct Dosage of GS-441524 (NeoFipronis)
Feline Infectious Peritonitis (FIP) is a severe and often fatal disease caused by a mutated feline coronavirus that affects cats worldwide. Symptoms include inappetence, lethargy, fever, abdominal and thoracic effusions, lymphadenopathy, granulomatous inflammation, neurological impairment, and uveitis. Until recently, effective treatment options were limited, but the emergence of GS-441524 has revolutionized FIP management, offering hope for many affected cats. NeoFipronis, also known as Pronidesivir, is the world's first officially registered oral medication specifically approved for FIP treatment, with comprehensive clinical validation.
GS-441524, the active component of NeoFipronis, is a nucleoside analog with potent antiviral activity against feline coronavirus. Developed through extensive research and clinical trials, GS-441524 inhibits viral replication effectively, leading to significant clinical improvement in cats with FIP. NeoFipronis's safety profile, rapid absorption, and minimal adverse effects make it an ideal therapeutic option for FIP.
Dosage guidelines are critical for optimizing treatment outcomes while minimizing risks. The standard dosage recommendation is based on the cat's body weight, with an initial dose of 15 mg per kilogram of body weight administered once daily. This dosage equates to half a tablet or dose unit per kilogram, ensuring effective antiviral activity. For cats exhibiting neuro or ocular symptoms, which often require more aggressive treatment, the dose should be increased to 30 mg/kg, but only under veterinary supervision and guidance.
Administer NeoFipronis on an empty stomach—either one hour before feeding or two hours after—to enhance absorption. Consistency is essential; treatment must be continuous for no less than 12 weeks to achieve the best chances of viral clearance. Skipping doses or interruption in therapy can lead to relapse or development of drug resistance. Regular monitoring of clinical signs, including appetite, body temperature, and activity level, is vital throughout the treatment course.
Periodic blood tests are recommended to assess liver and kidney functions, as well as complete blood counts, to detect any adverse effects early. While NeoFipronis is an over-the-counter medication, veterinary guidance is strongly advised for dosage adjustments, managing side effects, and ensuring comprehensive care for the infected cat.
NeoFipronis's approval by the Laos Ministry of Agriculture and Forestry in March 2026 marks a milestone in veterinary medicine, providing a safe, non-invasive, and effective oral treatment for FIP. Its rapid onset of action, good tolerability, and high safety margin set it apart from previous experimental therapies. Pet owners should purchase NeoFipronis exclusively through official channels—such as the official NeoFipronis website—to ensure product authenticity and quality.
Precautions include strictly adhering to the prescribed treatment duration—no less than 12 weeks—and avoiding off-label use. Keep medication out of reach of children and humans to prevent misuse. The medication is intended solely for feline use, and human consumption should be strictly avoided. Always consult a veterinarian before starting or adjusting therapy and report any adverse reactions promptly.
In summary, the correct dosage of GS-441524 (NeoFipronis) depends on the cat’s weight and symptom severity, with a typical range of 15-30 mg/kg daily. Consistent administration, veterinary oversight, and regular monitoring are essential to maximize therapeutic benefits in cats afflicted with FIP. NeoFipronis represents a breakthrough in feline medicine, transforming FIP from a death sentence into a manageable disease for many cats worldwide.
